|
Stories from the dialysis comunity across the globe.
|
|
Research and Markets: Dialysis Catheters Market in the US 2015-2019: The ... - Business Wire (press release) |
 |
 |
|
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4m8frw/dialysis) has announced the addition of the "Dialysis Catheters Market in the US 2015-2019" report to their offering.
The analysts forecast the dialysis catheters market in the US to grow at a CAGR of 2.11% over the period 2015-2019.
The report, the Dialysis Catheters Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the dialysis catheters market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key vendors
- AngioDynamics
- C.R. Bard
- Covidien
- Medical Components
Other prominent vendors
- Argon Medical Devices
- Baxter International
- Merit Medical Systems
- Teleflex
Commenting on the report, an analyst from the team said: The use of minimally invasive techniques to manage patients with cancer, certain congenital malformations, gastrointestinal malfunction, and need long-term access to medications or dialysis has increased. Minimally invasive dialysis catheters meet the needs of patients who require short or long-term therapy in many clinical settings. In addition, their usage also reduces the risk of infection from changing sites, causes minimal complications, and provides proper care and maintenance.
According to the report, the growing ESRD and CKD patient population has increased the demand for hemodialysis and dialysis catheters for vascular access. In the US, 11,813 people were estimated to have contracted ESRD in 2012.
For more information visit http://www.researchandmarkets.com/research/4m8frw/dialysis
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
|
|
|
Podocyte biology Free fatty acid-induced macropinocytosis in podocytes - Nature.com |
|
|
Nature.com
Podocytes have long been known to contain large intracellular vesicles, but the functional relevance of these vesicles has remained unclear. Findings now suggest that these vesicles are involved in macropinocytosis, enabling podocytes to internalize
|
|
Outcomes poor among HIV/HCV coinfected kidney transplant recipients - Healio |
|
|
|
Outcomes after kidney transplantation were worse among patients coinfected with HIV and hepatitis C virus when compared with those without either infection or HIV alone, according to recent data.
“Kidney transplantation is now offered as an acceptable treatment option for HIV-positive end-stage renal disease patients and has expanded beyond the scope of clinical trials,” the researchers wrote. “Although this marks a new era in the care of the HIV-positive ESRD patient, experience with HIV-positive kidney transplantation remains in its relative infancy.
“Concerns remain regarding the high incidence of acute rejection after HIV-positive kidney transplantation and its possible effect on long-term transplant outcomes.”
Using data recorded in the Scientific Registry of Transplant Recipients from 2002 to 2011, researchers analyzed graft and long-term survival data from 510 adult kidney transplant recipients with HIV and 94,948 recipients without HIV. On average, recipients with HIV were younger, less likely to be obese, and more often male and black, compared with recipients without HIV. Kidney recipients with HIV also were more likely to have HCV infection (24.2% vs. 5.5%; P<.001).
Graft survival at 5 and 10 years was lower among the HIV cohort when compared with patients without HIV (HR = 1.37; 95% CI, 1.15-1.64); however, no difference was seen when comparing HIV monoinfected recipients to those without HIV and HCV (HR = 1.06; 95% CI, 1.85-1.33). Worse graft survival was reported among HIV/HCV coinfected recipients vs. those with HCV alone (HR = 1.38; 95% CI, 1.08-1.77). These trends persisted when controlling for death.
Similar results were observed among patient survival rates. Recipients with HIV were less likely to survive when compared with recipients without HIV (HR = 1.34; 95% CI, 1.08-1.68), but not when either group was infected with HCV (HR = 1.26; 95% CI, 0.98-1.69). Decreased patient survival was observed among coinfected recipients compared with controls with HCV only (HR =1.57; 95% CI, 1.11-2.23).
“These results are encouraging, but they do suggest caution in transplanting HIV-positive recipients coinfected with HCV, motivating future studies of survival benefit,” the researchers wrote. — by Dave Muoio
Disclosure:The researchers report no relevant financial disclosures.
|
|
|
Proteinuria Found to Have Predictive Value for Good Long-Term Renal Outcome ... - Lupus News Today |
|
|
You may also like....
 Phase II Clinical Trial Combining Abatacept and Cyclophosphamide for Lupus Nephritis Yields Poor Results
 UAB Researchers Develop a Decision Aid Program on Lupus Therapy Options
 Researchers Find New Biomarkers for Severe Lupus Nephritis
A study recently published in the journal Arthritis & Rheumatology revealed that proteinuria is an accurate clinical predictor of long-term renal outcome in patients with lupus nephritis. The study was conducted by an international research team and is entitled “Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort.”
Systemic lupus erythematosus (SLE) is a severe autoimmune disease in which the body’s own immune system is abnormally activated leading to an attack of healthy joints and organs, resulting in inflammation, swelling, pain, disability and often in tissue destruction and multi-organ damage. When the immune system attacks the kidney it becomes inflamed, a process known as lupus nephritis, one of the most severe complications in SLE patients that can lead to long-term damage, kidney failure and death. There is no approved drug treatment for lupus nephritis.
In order to conduct proper lupus nephritis trials, it is necessary to establish which response measures are the most predictive in terms of good long-term kidney function. In the study, researchers assessed whether proteinuria (the excess of serum proteins in the urine), serum creatinine (Cr, a product of muscle metabolism) and urinary red blood cells (RBCs) could be used as accurate clinical predictors of good long-term renal outcome (defined as a serum Cr value ? 1.0 mg/dL).
The research team analyzed data available from 76 patients in the Euro-Lupus Nephritis Trial, who had 3, 6, or 12 months measurements of proteinuria, serum Cr and urinary RBC, with a minimum follow-up period of 7 years. The specificity and sensitivity of each biomarker was determined.
Researchers found that the best clinical predictor of good long-term renal function at 7 years was proteinuria with a value of < 0.8 gm/day at 12 months, with a sensitivity of 81% and specificity of 78%. Combining proteinuria and serum Cr as a composite predictor had no benefit in terms of improving sensitivity and specificity, while the combination of urinary RBCs significantly decreased sensitivity to 47%.
The research team concluded that the level of proteinuria at 12 months is the best single predictor of long-term renal outcome in patients with lupus nephritis. Researchers also suggest that since urinary RBCs have a poor predictive value, they should not be considered as a response measure in clinical trials for lupus nephritis.
Share this article
 Patricia Silva, PhD
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
|
|
Amgen gets injunction against Novartis biosimilar drug - NephrologyNews.com |
|
|
|
|
|
|
<< Start < Prev 241 242 243 244 245 246 247 248 249 250 Next > End >>
|
|
Page 241 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
